Vedere Bio II

Developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due photoreceptor death.

[Vedere Bio II @VedereBio]

Vedere Bio II was excited to be included as part of LabCentral's 238 Grand Opening. We even had some special guests visit our lab! #biotech #genetherapy #optogenetics

[Vedere Bio II @VedereBio]

Today, Vedere Bio II announces that Russell Kelley, Ph.D., Managing Director of the @RD_Fund, will replace Benjamin Yerxa, Ph.D. as Board observer. We'd like to thank Ben for his valuable contributions to the Board and are honored to have Rusty join us!

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to present positive new data supporting its proprietary platform at #ASGCT22! Read more here: https://t.co/Z9qqWS1I5y

[Vedere Bio II @VedereBio]

Today, Vedere Bio II announced that we will present two abstracts at the 25th Annual @ASGCTherapy meeting. Learn more about what this means for the company here: https://t.co/Z9qqWS1I5y #ASGCT22

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to welcome Anna Demetriades, M.D., PH.D. as Chief Medical Officer! Get a better view on the Vedere news here:https://t.co/Z9qqWS1I5y
#biotech #genetherapy #optogenetics

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to welcome Gina Consylman as Chief Financial Officer! Get a better view on the Vedere news here: https://t.co/Z9qqWS1I5y #biotech #genetherapy #optogenetics

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to welcome Martina Schinke as Vice President, Program Leader! https://t.co/TZnMblS00O #genetherapy #biotech #optogenetics

[Vedere Bio II @VedereBio]

“@Vedere is proud to be included on the list of the 10 largest Series A financings of 2021 in Massachusetts biotech! https://t.co/OfSNZVatzi #genetherapy #opthlamology #optogenetics

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to welcome Michael Murtagh as Senior Vice President, Regulatory Affairs! #genetherapy #biotech #optogenetics

[Vedere Bio II @VedereBio]

Vedere Bio II is pleased to welcome Meihua Ju, as Vice President, Preclinical! #genetherapy #biotech

[Vedere Bio II @VedereBio]

Proud to partner with you again to bring next generation vision restoration treatments to patients.
RD Fund: Where We’ve Been & Where We’re Going https://t.co/2GZZHHBWzY

[Vedere Bio II @VedereBio]

We are pleased to welcome Gabor Veres as Chief Scientific Officer! With 20 yrs of experience developing cell & #genetherapy products, Dr. Veres will provide invaluable counsel as we continue our work to rapidly restore vision to patients. https://t.co/7f8RQZ9jjo #biotech

[Vedere Bio II @VedereBio]

Today, we are thrilled to announce the launch of Vedere Bio II! Vedere Bio II (Vedere) is pioneering beyond traditional #genetherapy to not just slow vision loss, but actually restore it. Read more here: https://t.co/Z9qqWS1I5y #bionews

[Vedere Bio II @VedereBio]

Our President & CEO, Cyrus Mozayeni, spoke with @AlexWestchester from @GENbio! Read the interview here https://t.co/z4cIyANezw, and take a deeper dive into what #optogenetics is, how @VedereBio came to be acquired by @Novartis, and future plans for Vedere Bio II!

[Vedere Bio II @VedereBio]

#ICYMI: Yesterday @VedereBio was acquired by @Novartis #ophthalmology #bionews

[Vedere Bio II @VedereBio]

Today @VedereBio is proud to announce the launch of Vedere Bio ll, our new ocular gene therapy company leveraging a toolbox to develop a pipeline of vision restoration and vision preservation therapies: https://t.co/T01v8bkDWT #ophthalmology #bionews

[Vedere Bio II @VedereBio]

Today @VedereBio announced we’ve been acquired by @Novartis. We’re excited to get our programs in the hands of an innovative company that will push forward our mission to deliver functional vision to patients in need. Details here: https://t.co/W8b3ZrYtkl #ophthalmology #bionews